Bleeding with concomitant ibrutinib and oral anticoagulant therapy: A population-based cohort study.
作者信息
Dhopeshwarkar Neil, Yang Wei, Hennessy Sean, Rhodes Joanna M, Cuker Adam, Leonard Charles E
机构信息
Center for Real-world Effectiveness and Safety of Therapeutics and the Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
出版信息
Am J Hematol. 2023 Mar;98(3):E49-E52. doi: 10.1002/ajh.26802. Epub 2022 Dec 7.
Abstract
摘要
相似文献
1
Bleeding with concomitant ibrutinib and oral anticoagulant therapy: A population-based cohort study.依鲁替尼与口服抗凝剂联合治疗时的出血情况：一项基于人群的队列研究。
Am J Hematol. 2023 Mar;98(3):E49-E52. doi: 10.1002/ajh.26802. Epub 2022 Dec 7.
2
Bleeding risk with concurrent use of anticoagulants and ibrutinib: A population-based nested case-control study.同时使用抗凝药物和伊布替尼的出血风险：一项基于人群的巢式病例对照研究。
Br J Haematol. 2023 Oct;203(2):311-318. doi: 10.1111/bjh.18995. Epub 2023 Jul 24.
3
Ibrutinib in patients with atrial fibrillation - the challenge of thromboembolic prophylaxis.伊布替尼治疗心房颤动患者 - 血栓栓塞预防的挑战。
Rom J Intern Med. 2021 Aug 26;59(3):270-277. doi: 10.2478/rjim-2021-0015. Print 2021 Sep 1.
4
Reversal of antithrombotic agents.抗血栓药物的逆转。
Am J Hematol. 2012 May;87 Suppl 1:S119-26. doi: 10.1002/ajh.23165. Epub 2012 Mar 28.
5
Direct oral anticoagulant reversal: An update.直接口服抗凝剂逆转：最新进展。
Nursing. 2021 Jun 1;51(6):54-64. doi: 10.1097/01.NURSE.0000743104.69943.67.
6
Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies.依鲁替尼相关出血：发病机制、管理及风险降低策略
J Thromb Haemost. 2017 May;15(5):835-847. doi: 10.1111/jth.13651. Epub 2017 Mar 27.
7
Outcomes of direct oral anticoagulant- and warfarin-associated hemorrhage: A single center retrospective cohort study.
Thromb Res. 2020 May;189:128-131. doi: 10.1016/j.thromres.2019.09.001. Epub 2019 Sep 3.
8
Treatment of acute bleeding with recombinant factor VIIa in a patient with IgA deficit receiving anticoagulant therapy.
Acta Haematol. 2003;110(1):51-2. doi: 10.1159/000072418.
9
Bleeding related to oral anticoagulants: Trends in US emergency department visits, 2016-2020.与口服抗凝剂相关的出血：2016-2020 年美国急诊科就诊趋势。
Thromb Res. 2023 May;225:110-115. doi: 10.1016/j.thromres.2023.03.010. Epub 2023 Mar 29.
10
Specific antidotes for bleeding associated with direct oral anticoagulants.直接口服抗凝剂相关出血的特效解毒剂。
BMJ. 2017 May 25;357:j2216. doi: 10.1136/bmj.j2216.
引用本文的文献
1
Anticoagulation in Patients With Cancer.癌症患者的抗凝治疗
JACC Case Rep. 2024 Nov 20;29(22 Suppl):102684. doi: 10.1016/j.jaccas.2024.102684.
本文引用的文献
1
Rate of major bleeding with ibrutinib versus bendamustine-rituximab in chronic lymphocytic leukemia: A population-based cohort study.依鲁替尼与苯达莫司汀-利妥昔单抗治疗慢性淋巴细胞白血病时的大出血发生率：一项基于人群的队列研究。
Am J Hematol. 2022 Sep;97(9):E332-E335. doi: 10.1002/ajh.26632. Epub 2022 Jun 24.
2
The risk of bleeding in patients receiving ibrutinib combined with novel direct oral anticoagulants.接受依鲁替尼联合新型直接口服抗凝剂治疗的患者的出血风险。
Br J Haematol. 2020 Apr;189(2):e31-e33. doi: 10.1111/bjh.16422. Epub 2020 Mar 9.
3
Ibrutinib-Associated Atrial Fibrillation.伊布替尼相关心房颤动。
JACC Clin Electrophysiol. 2018 Dec;4(12):1491-1500. doi: 10.1016/j.jacep.2018.06.004. Epub 2018 Aug 29.
4
Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis.依鲁替尼治疗患者大出血的发生率和风险因素：一项综合分析。
Br J Haematol. 2019 Feb;184(4):558-569. doi: 10.1111/bjh.15690. Epub 2018 Dec 2.
5
An automated database case definition for serious bleeding related to oral anticoagulant use.一种用于口服抗凝剂相关严重出血的自动化数据库病例定义。
Pharmacoepidemiol Drug Saf. 2011 Jun;20(6):560-6. doi: 10.1002/pds.2109. Epub 2011 Mar 8.
6
Accuracy of coding for possible warfarin complications in hospital discharge abstracts.医院出院摘要中对华法林可能并发症的编码准确性。
Thromb Res. 2006;118(2):253-62. doi: 10.1016/j.thromres.2005.06.015. Epub 2005 Aug 2.
Zotero 插件